CD8A and neoplasm: In order to determine whether IL-32 treatment resulted in increased tumor antigen-reactive CD8+ T cells, we assessed their specificity for MHC class I tetrameric complexes bearing SVYDFFVWL peptides derived from tyrosinase-related protein 2 (TRP-2).